Psychiatry Is Still Stuck in Freud ’s Era. Big Data Can Revolutionize How We Care for Patients
I have a problem. I am a psychiatrist in the 21st century and yet I still evaluate patients the way Freud did a century ago: I sit with a patient and, by carefully observing how and what they say, I expect them to tell me what’s wrong. The problem isn’t that I speak with and listen to my patients. Every doctor of every speciality does that. Rather, my problem is that I never measure the data I think are most important to my treatment of psychiatric diseases. Consider how I evaluate a patient for psychosis in the emergency room. When I speak with them, I want to know what their life is like—what’s th...
Source: TIME: Health - July 9, 2021 Category: Consumer Health News Authors: Daniel Barron Tags: Uncategorized Source Type: news

RSNA announces 2021 meeting highlights
The RSNA has announced program highlights ahead of its 2021 annual meeting t...Read more on AuntMinnie.comRelated Reading: RSNA announces MIDRC funding program RSNA R&E grant study identifies new biomarker for NSCLC RSNA plans for in-person meeting in 2021 Top healthcare trends on display at RSNA 2020 FDG-PET/CT within a year of heart valve surgery looks safe (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - June 24, 2021 Category: Radiology Source Type: news

Janssen Submits New Drug Application to U.S. FDA for XARELTO ® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients
RARITAN, NJ, June 23, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the use of XARELTO® (rivaroxaban) in pediatric patients. The NDA seeks two pediatric indications: treatment of venous thromboembolism (VTE, or blood clots) and reduction in the risk of recurrent VTE in patients aged birth to less than 18 years of age after at least five days of initial parenteral anticoagulant treatment; and thromboprophylaxis (prevention of blood clots) in patients aged 2 years and older with congenita...
Source: Johnson and Johnson - June 23, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

No Benefit to Postop Heparin Bridging in Patients Who Stop Warfarin for a Procedure No Benefit to Postop Heparin Bridging in Patients Who Stop Warfarin for a Procedure
There does not appear to be a benefit to postoperative heparin bridging in patients with atrial fibrillation or a mechanical heart valve who temporarily stop taking warfarin before a planned procedure, according to results of the PERIOP2 study.Reuters Health Information (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - June 18, 2021 Category: Surgery Tags: Cardiology News Source Type: news

Late-Breaking Data at ACC.21 Show XARELTO ® (rivaroxaban) Plus Aspirin Significantly Reduced Total Ischemic Events in Peripheral Artery Disease (PAD) Patients After Lower-Extremity Revascularization
RARITAN, N.J., May 16, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today presented new data from the Phase 3 VOYAGER PAD study which showed XARELTO® (rivaroxaban) (2.5 mg twice daily) in combination with aspirin (100 mg once daily) consistently reduced severe vascular events in patients with peripheral artery disease (PAD) after lower-extremity revascularization (LER) compared to aspirin alone regardless of whether it was the first, second, third, or subsequent event. The primary results of VOYAGER PAD showed that XARELTO® plus aspirin reduced first events by 15 percent among patients with PAD ...
Source: Johnson and Johnson - May 16, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

AHA News: After Two Heart Valve Surgeries, a Mental Toll
Title: AHA News: After Two Heart Valve Surgeries, a Mental TollCategory: Health NewsCreated: 4/20/2021 12:00:00 AMLast Editorial Review: 4/21/2021 12:00:00 AM (Source: MedicineNet Heart General)
Source: MedicineNet Heart General - April 21, 2021 Category: Cardiology Source Type: news

AHA News: After Two Heart Valve Surgeries, a Mental Toll
TUESDAY, April 20, 2021 (American Heart Association News) -- After Ivan Hernandez was born with a defective mitral valve, doctors warned his parents he could face heart failure at any age. Yet Hernandez grew up without incident. He played all sorts... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - April 20, 2021 Category: General Medicine Source Type: news

Abbott Receives CE Mark Approval for Next-Generation TriClip(TM) Device, Offering New Innovations for Tricuspid Heart Valve Repair
New enhancements to first-of-its-kind device uniquely developed for the difficult-to-treat tricuspid valve Next-generation therapy offers enhanced leaflet grasping feature and new clip sizes to fit each patient's complex tricuspid valve anatomy TriCl... Devices, Interventional, Cardiology, Regulatory Abbott, TriClip, Transcatheter, Tricuspid Valve Repair, Tricuspid Valve (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - April 8, 2021 Category: Pharmaceuticals Source Type: news

Abbott Receives CE Mark Approval for Next-Generation TriClip ™ Device, Offering New Innovations for Tricuspid Heart Valve Repair
- New enhancements to first-of-its-kind device uniquely developed for the difficult-to-treat tricuspid valve (Source: Abbott.com)
Source: Abbott.com - April 8, 2021 Category: Pharmaceuticals Source Type: news

FDA Approves First Nonsurgical Heart Valve for Congenital Heart Disease
MONDAY, March 29, 2021 -- The first-ever nonsurgical heart valve to treat patients with severe pulmonary valve regurgitation, often resulting from congenital heart disease, was approved by the U.S. Food and Drug Administration, the agency announced... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 29, 2021 Category: Pharmaceuticals Source Type: news

Lab-Made Heart Valves Can Grow Along With Youngest Heart Patients
MONDAY, March 22, 2021 -- Lab-created heart valves that grow with the recipient could spare kids born with heart defects from the repeated valve-replacement surgeries they now endure. University of Minnesota researchers found that lab-created valves... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - March 22, 2021 Category: General Medicine Source Type: news

Lab-Made Heart Valves Can Grow Along With Youngest Heart Patients
Title: Lab-Made Heart Valves Can Grow Along With Youngest Heart PatientsCategory: Health NewsCreated: 3/22/2021 12:00:00 AMLast Editorial Review: 3/22/2021 12:00:00 AM (Source: MedicineNet Heart General)
Source: MedicineNet Heart General - March 22, 2021 Category: Cardiology Source Type: news

Artificial Heart Valves Grow with Lambs
Two of the implanted valves lasted a full year as the animals matured into adult sheep, demonstrating that it might be possible to treat children with valve replacements that grow along with them. (Source: The Scientist)
Source: The Scientist - March 19, 2021 Category: Science Tags: News & Opinion Source Type: news

Tri-tube heart valve replacement adapts to the growing heart in lambs
(American Association for the Advancement of Science) Combining tissue engineering and regenerative medicine, scientists have fabricated a series of heart valve replacements with the ability to incorporate host cells, enabling them to regenerate and grow over time. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 17, 2021 Category: International Medicine & Public Health Source Type: news